| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
Human Endogenous Metabolite
1-Methylnicotinamide chloride targets the endothelium and the prostacyclin pathway. It exerts antithrombotic and anti-inflammatory properties through direct action on the endothelium by a mechanism involving the prostacyclin pathway and by improving nitric oxide bioavailability. It also modulates cellular redox status. |
|---|---|
| ln Vitro |
G-actin polymerization is observed after 12 and 24 hours of treatment with TRIA-662 (0.1–10 μM) [1]. Endothelial cells demonstrate anti-inflammatory effect towards TRIA-662 (0.05-0.2 μM; 1-24 hours) [1].
In vitro, 1-Methylnicotinamide chloride demonstrates antithrombotic and anti-inflammatory properties. It acts on the endothelium through the prostacyclin pathway and improves nitric oxide bioavailability. It modulates cellular redox status and controls signaling and transcriptional events. It is used in studies of inflammation and thrombosis. |
| ln Vivo |
In vivo, 1-Methylnicotinamide chloride exerts antithrombotic activity mediated by a cyclooxygenase-2/prostacyclin pathway. It demonstrates anti-inflammatory properties through direct action on the endothelium. As a primary metabolite of nicotinamide, it is involved in NAD and NADP metabolism, which serve essential functions in modulating cellular redox status and controlling signaling and transcriptional events.
|
| Enzyme Assay |
In vitro assays for 1-Methylnicotinamide chloride typically involve endothelial cell culture studies. Endothelial cells are treated with MNA at concentrations ranging from 0.1-100 µM. Prostacyclin production is measured by ELISA. Nitric oxide bioavailability is assessed by measuring NO production. Anti-inflammatory effects are evaluated by measuring cytokine production in stimulated endothelial cells.
|
| Cell Assay |
Immunofluorescence[1]
Cell Types: HMECs Tested Concentrations: 0.1 and 10 μM Incubation Duration: 12 and 24 hrs (hours) Experimental Results: demonstrated polymerization of the G-actin, and strong, clearly visible, parallel F-actin fibers at 10 μM. For in vitro cell assays, endothelial cells are cultured and treated with 1-Methylnicotinamide chloride at various concentrations. Cell viability is assessed by MTT assay. Prostacyclin (PGI2) production is measured by ELISA. Nitric oxide levels are measured using Griess reagent or DAF-FM fluorescence. Inflammatory markers (e.g., ICAM-1, VCAM-1) are assessed by qPCR or ELISA. |
| Animal Protocol |
For in vivo animal studies, 1-Methylnicotinamide chloride is typically administered to rodents via oral gavage or intravenous injection in models of thrombosis and inflammation. Antithrombotic efficacy is evaluated in arterial thrombosis models. Anti-inflammatory effects are assessed in models of inflammation. Plasma MNA levels are quantified by LC-MS/MS.
|
| ADME/Pharmacokinetics |
1-Methylnicotinamide chloride (MW 172.61) has the molecular formula C7H9ClN2O. It is a chloride salt form of 1-methylnicotinamide, a primary metabolite of nicotinamide. The compound is soluble in water and stable under recommended storage conditions. It is also known as trigonellamide chloride or nicotinamide methochloride.
|
| Toxicity/Toxicokinetics |
The compound is for research use only. No specific toxicity data are available. As a metabolite of nicotinamide, it is expected to have low toxicity at physiological concentrations. However, its effects on the endothelium and prostacyclin pathway suggest potential cardiovascular effects at higher doses. Standard laboratory safety precautions should be followed.
|
| References | |
| Additional Infomation |
1-Methylnicotinamide chloride (CAS# 1005-24-9) is a primary metabolite of nicotinamide produced by NNMT. It has not been approved as a therapeutic drug but is studied for its antithrombotic and anti-inflammatory properties. The compound is used in research on thrombosis, inflammation, and NAD metabolism. It is also known as MNA or trigonellamide chloride.
|
| Molecular Formula |
C7H9CLN2O
|
|---|---|
| Molecular Weight |
172.61
|
| Exact Mass |
172.04
|
| CAS # |
1005-24-9
|
| Related CAS # |
TRIA-662-d3;1218993-18-0
|
| PubChem CID |
70495
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
207-209℃ (water acetone )
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
11
|
| Complexity |
136
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[Cl-].O=C(C1C([H])=C([H])C([H])=[N+](C([H])([H])[H])C=1[H])N([H])[H]
|
| InChi Key |
BWVDQVQUNNBTLK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C7H8N2O.ClH/c1-9-4-2-3-6(5-9)7(8)10;/h2-5H,1H3,(H-,8,10);1H
|
| Chemical Name |
1-methylpyridin-1-ium-3-carboxamide;chloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 110 mg/mL (637.27 mM)
DMSO: 2 mg/mL (11.59 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (7.24 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (7.24 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. View More
Solubility in Formulation 3: 100 mg/mL (579.34 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.7934 mL | 28.9670 mL | 57.9341 mL | |
| 5 mM | 1.1587 mL | 5.7934 mL | 11.5868 mL | |
| 10 mM | 0.5793 mL | 2.8967 mL | 5.7934 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
